<SEC-DOCUMENT>0001999371-25-021194.txt : 20251229
<SEC-HEADER>0001999371-25-021194.hdr.sgml : 20251229
<ACCEPTANCE-DATETIME>20251229074544
ACCESSION NUMBER:		0001999371-25-021194
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20251229
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251229
DATE AS OF CHANGE:		20251229

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tonix Pharmaceuticals Holding Corp.
		CENTRAL INDEX KEY:			0001430306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				261434750
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36019
		FILM NUMBER:		251603102

	BUSINESS ADDRESS:	
		STREET 1:		26 MAIN STREET, SUITE 101
		CITY:			CHATHAM
		STATE:			NJ
		ZIP:			07928
		BUSINESS PHONE:		212-980-9155

	MAIL ADDRESS:	
		STREET 1:		26 MAIN STREET, SUITE 101
		CITY:			CHATHAM
		STATE:			NJ
		ZIP:			07928

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TAMANDARE EXPLORATIONS INC.
		DATE OF NAME CHANGE:	20080320
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tonix-8k_122925.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:TNXP="http://TNXP/20251229">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_TNXP_TNXP_20251229 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20251229_20251229 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05B_edei%2D%2DEntityCentralIndexKey_0001430306 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-12-29" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-12-29" id="Fact000004" name="dei:EntityCentralIndexKey">0001430306</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="tnxp-20251229.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-12-29">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-12-29</xbrli:startDate>
        <xbrli:endDate>2025-12-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>



<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->


<p style="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNITED STATES&#160;</b></p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION&#160;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>


<p style="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM <span id="xdx_90F_edei--DocumentType_c20251229__20251229_zw5rig6cVDAh"><ix:nonNumeric contextRef="AsOf2025-12-29" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of report (date of earliest event reported):
<b><span id="xdx_903_edei--DocumentPeriodEndDate_c20251229__20251229_zDb70qEIeBXb"><ix:nonNumeric contextRef="AsOf2025-12-29" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">December
29, 2025</ix:nonNumeric></span></b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 20pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="xdx_908_edei--EntityRegistrantName_c20251229__20251229_zLUeXOZQ0she"><ix:nonNumeric contextRef="AsOf2025-12-29" id="Fact000011" name="dei:EntityRegistrantName">TONIX PHARMACEUTICALS HOLDING CORP.</ix:nonNumeric></span></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityIncorporationStateCountryCode_c20251229__20251229_zW6qqgbcmqod"><ix:nonNumeric contextRef="AsOf2025-12-29" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="font: 12pt Times New Roman, Times, Serif; width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityFileNumber_c20251229__20251229_zNVF3ACVnZBj"><ix:nonNumeric contextRef="AsOf2025-12-29" id="Fact000013" name="dei:EntityFileNumber">001-36019</ix:nonNumeric></span></b></span></td>
    <td style="font: 12pt Times New Roman, Times, Serif; width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityTaxIdentificationNumber_c20251229__20251229_zvVxIJvM1MZj"><ix:nonNumeric contextRef="AsOf2025-12-29" id="Fact000014" name="dei:EntityTaxIdentificationNumber">26-1434750</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(State
                                            or Other Jurisdiction&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>of Incorporation)&#160;</b></p></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Commission&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>File Number)</b></p></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(IRS
                                            Employer&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Identification No.)&#160;</b></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="xdx_901_edei--EntityAddressAddressLine1_c20251229__20251229_zwM3yHQ0Bsni"><ix:nonNumeric contextRef="AsOf2025-12-29" id="Fact000015" name="dei:EntityAddressAddressLine1">26
Main Street</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressCityOrTown_c20251229__20251229_ziSARWL2Vsil"><ix:nonNumeric contextRef="AsOf2025-12-29" id="Fact000016" name="dei:EntityAddressCityOrTown">Chatham</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressStateOrProvince_c20251229__20251229_zk5ohd5JNtC4"><ix:nonNumeric contextRef="AsOf2025-12-29" format="ixt-sec:stateprovnameen" id="Fact000017" name="dei:EntityAddressStateOrProvince">New
Jersey</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressPostalZipCode_c20251229__20251229_zxvGoSeOnOja"><ix:nonNumeric contextRef="AsOf2025-12-29" id="Fact000018" name="dei:EntityAddressPostalZipCode">07928</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices) (Zip
Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant&#8217;s telephone number, including
area code: <span id="xdx_907_edei--CityAreaCode_c20251229__20251229_zY1DrWcSePxa"><ix:nonNumeric contextRef="AsOf2025-12-29" id="Fact000019" name="dei:CityAreaCode">(862)</ix:nonNumeric></span>
<span id="xdx_904_edei--LocalPhoneNumber_c20251229__20251229_zDWpkuveTBki"><ix:nonNumeric contextRef="AsOf2025-12-29" id="Fact000020" name="dei:LocalPhoneNumber">799-8599</ix:nonNumeric></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span id="xdx_901_edei--WrittenCommunications_c20251229__20251229_zNVHrKA2Q4re"><ix:nonNumeric contextRef="AsOf2025-12-29" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span> Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_904_edei--SolicitingMaterial_c20251229__20251229_z4DS7fJmEV58"><ix:nonNumeric contextRef="AsOf2025-12-29" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span> Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_905_edei--PreCommencementTenderOffer_c20251229__20251229_zc1q3dkp5j9e"><ix:nonNumeric contextRef="AsOf2025-12-29" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span> Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_907_edei--PreCommencementIssuerTenderOffer_c20251229__20251229_z83ZQCxD9gW6"><ix:nonNumeric contextRef="AsOf2025-12-29" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span> Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">Securities registered pursuant
to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; font: 12pt Times New Roman, Times, Serif; vertical-align: bottom; width: 25%; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each class</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; vertical-align: bottom; width: 27%; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol(s)</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; vertical-align: bottom; width: 48%; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each exchange on which registered</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 12pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 5.4pt; text-align: center"><span style="font: bold 10pt Times New Roman, Times, Serif"><span id="xdx_907_edei--Security12bTitle_c20251229__20251229_zwZ5uOT6ea36"><ix:nonNumeric contextRef="AsOf2025-12-29" id="Fact000025" name="dei:Security12bTitle">Common Stock</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 5.4pt; text-align: center"><span style="font: bold 10pt Times New Roman, Times, Serif"><span id="xdx_906_edei--TradingSymbol_c20251229__20251229_zPpudHRcqLCh"><ix:nonNumeric contextRef="AsOf2025-12-29" id="Fact000026" name="dei:TradingSymbol">TNXP</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 5.4pt; text-align: center"><span style="font: bold 10pt Times New Roman, Times, Serif">The <span id="xdx_906_edei--SecurityExchangeName_c20251229__20251229_zo8mZeToREBi"><ix:nonNumeric contextRef="AsOf2025-12-29" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">Emerging growth company <span id="xdx_902_edei--EntityEmergingGrowthCompany_c20251229__20251229_zgaGGmmC5IUg"><ix:nonNumeric contextRef="AsOf2025-12-29" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p>



<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"></p>



<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 10%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 7.01</b></span></td>
    <td style="width: 90%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulation FD Disclosure.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 29, 2025, Tonix Pharmaceuticals
Holding Corp. (the &#8220;Company&#8221;) announced program updates on its TNX-4800 product candidate for protection against Lyme disease.
A copy of the press release which discusses this matter is furnished hereto as Exhibit 99.01, and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The information in this Item 7.01
of this Current Report on Form&#160;8-K, including Exhibit 99.01 attached hereto, shall not be deemed &#8220;filed&#8221; for purposes
of Section 18 of the United States Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities
of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the
Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 10%"><b>Item 8.01.</b></td><td style="width: 90%"><b>Other Events.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 29, 2025, the Company announced that it plans to meet with
the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in 2026 to explore Phase 2/3 development options for TNX-4800. The Company believes
that a controlled human infection model study using <i>Borrelia</i>-infected ticks that mimic natural infection would be a potential path
to demonstrating TNX 4800 efficacy for potential FDA approval, and that it may have investigational product produced under Good Manufacturing
Practices (GMP) available for testing early in 2027. The Company further believes that (i) prophylaxis with TNX-4800 may avoid the limitations
of vaccine products designed to actively immunize against Lyme disease, including suboptimal immune responses from age, immunocompetence,
and other reasons, and (ii) protection against <i>Borrelia</i> will require annual prophylaxis as exposed or infected individuals rarely
make antibodies against the outer surface protein A (OspA) of <i>Borrelia burgdorferi</i>, the causative agent of Lyme disease in humans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">TNX-4800 was studied in a randomized,
double-blind, sequential dose-escalation study that evaluated safety, tolerability, pharmacokinetics (&#8220;PK&#8221;), and immunogenicity
of TNX-4800 in healthy adults. Forty-four subjects were randomized and 41 completed the study. Subjects received a single subcutaneous
administration of placebo or TNX-4800 at 0.5, 1.5, 5, or 10 mg/kg. Safety was assessed by clinical and lab evaluations. Drug exposure
increased 25 times, for a 20 times increase in dose. Serum TNX-4800 was measurable at the earliest sampling time of 24 hours, indicating
rapid systemic absorption. TNX-4800 concentrations remained quantifiable for more than 200 days in 80% of volunteers at the lowest dose,
and for up to 350 days in the majority of volunteers at higher doses (i.e., &#8805; 1.5 mg/kg). Mean half-life ranged from 62 to 69 days
across groups. Serum concentrations remained quantifiable for up to 12 months in most subjects. Mean exposure for the 10 mg/kg cohort
was less than 20% of the highest exposures in a rat toxicology study. Anti-drug antibodies were detected in less than 10% of treated subjects,
with no impact on PK. Most adverse events were mild or moderate. TNX-4800 was determined to be generally safe and well tolerated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Forward-Looking Statements</i>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Current Report on Form 8-K
contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company&#8217;s product
development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future
results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking
statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate
and management&#8217;s current beliefs and assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">These statements may be identified
by the use of forward-looking expressions, including, but not limited to, &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221;
&#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221;
&#8220;should,&#8221; &#8220;would&#8221; and similar expressions and the negatives of those terms. These statements relate to future
events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results,
performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the
forward-looking statements. Such factors include those set forth in the Company&#8217;s filings with the SEC. Prospective investors are
cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company
undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 10%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 9.01</b></span></td>
    <td style="width: 90%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statements and Exhibits.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>






<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 2%; font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="vertical-align: bottom; width: 1%; font-size: 10pt; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 13%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exhibit</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>No.</b></p></td>
    <td style="vertical-align: bottom; width: 1%; font-size: 10pt; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 83%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description.</b></span></td></tr>
  <tr>
    <td style="vertical-align: top; font-size: 10pt; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><a href="ex99-01.htm">99.01</a></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">104</p></td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Press Release of the Company, December 29, 2025</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirement of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: bottom">
    <td style="padding-right: 3pt; padding-left: 3pt">&#160;</td>
    <td colspan="3" style="padding-right: 3pt; padding-left: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TONIX PHARMACEUTICALS HOLDING CORP.</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-right: 3pt; padding-left: 3pt">&#160;</td>
    <td colspan="3" style="padding-right: 3pt; padding-left: 3pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 50%; padding-right: 3pt; padding-left: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: December 29, 2025</span></td>
    <td style="width: 4%; padding-right: 3pt; padding-left: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </span></td>
    <td style="border-bottom: black 1pt solid; width: 23%; padding-right: 3pt; padding-left: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Bradley Saenger</span></td>
    <td style="width: 23%; padding-right: 3pt; padding-left: 3pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-right: 3pt; padding-left: 3pt">&#160;</td>
    <td colspan="3" style="padding-right: 3pt; padding-left: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bradley Saenger</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-right: 3pt; padding-left: 3pt">&#160;</td>
    <td colspan="3" style="padding-right: 3pt; padding-left: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>


<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjVsKwkAMRVfQPYT5lqrjA+mnRYtYRYqIv4ONMthOSmZ8LcldGlvEEMjrnhuleiqjpa2Q4Tgvcthj3VQmIBR4RkZ3QlGkq3UCUgu8WB/YuNCOPzAlYVCYaTwysm+Vd+uxTGCo+3rc1xNpkvEMdhsVfe8pubMt0QVrKjCuhB1TwxaD4VfnsDdPclS/2k8HZG/JiV086M5v0IOhhi3dzYP46iHPUxX12ohUxnRrRLV4BnRfEhYV1vLOd/Q/ow/OWEph -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.01
<SEQUENCE>2
<FILENAME>ex99-01.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><A HREF="tonix-8k_122925.htm">Tonix Pharmaceuticals Holding Corp. 8-K</A></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 99.01</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><IMG SRC="ex99_001.gif" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Tonix Pharmaceuticals Announces Program Updates
on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 1in; margin-left: 1in"><I>Exploring clinical development
plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive field study</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 1in; margin-left: 1in"><I>Expect to have investigational
product of TNX-4800 (anti-Borrelia OspA mAb) available for clinical trials in early 2027</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 1in; margin-left: 1in"><I>Approximately 70 million
people that live, work or vacation in areas of the U.S. in which Lyme Disease is endemic could potentially benefit from pre-exposure
prophylaxis </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>C</I>HATHAM, N.J., December 29, 2025 (GLOBE NEWSWIRE)
&ndash; Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (&ldquo;Tonix&rdquo; or the &ldquo;Company&rdquo;), a fully-integrated commercial
stage biotechnology company, today announced program updates on TNX-4800 (formerly known as mAb 2217LS)<SUP>1,2</SUP>, which is a long-acting
human monoclonal antibody (mAb) that targets the outer surface protein A (OspA) of <I>Borrelia burgdorferi</I>, the causative agent of
Lyme disease in humans. TNX-4800 is being developed for annual seasonal use, as one subcutaneous administration in the spring to protect
against Lyme disease through fall, or the entire tick season in the U.S. There are no currently marketed U.S. Food and Drug Administration
(FDA)-approved vaccines or prophylactics to protect against Lyme disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&ldquo;We plan to meet with the FDA in 2026 to explore Phase 2/3 development
options,&rdquo; said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. &ldquo;We believe a controlled human infection
model (CHIM)<SUP>3-5</SUP> study using <I>Borrelia</I>-infected ticks that mimics natural infection would be a potential path to demonstrating
TNX-4800 efficacy for approval. We are on a path to have investigational product produced under Good Manufacturing Practices (GMP) available
for testing early in 2027. We believe TNX-4800&rsquo;s long-acting mAb prophylaxis could play an important role for preventing Lyme for
millions of people who live, work, and vacation in regions endemic for Lyme disease. TNX-4800 provides near-immediate immunity to the
bacteria that cause Lyme disease after a single administration, which is very different from Lyme disease vaccine programs currently in
development. Prophylaxis with TNX-4800 may also avoid the limitations of vaccine products designed to actively immunize against Lyme,
including suboptimal immune responses from age, immunocompetence, and other reasons.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><IMG SRC="ex99_001.gif" ALT="">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About TNX-4800</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">TNX-4800 (formerly known as mAb 2217LS) is a fully
human monoclonal antibody with an engineered extended half-life that targets the outer-surface protein A (OspA) on Lyme-causing <I>Borrelia</I>
bacteria. By binding OspA when TNX-4800 containing blood is ingested by the tick, TNX-4800 kills and blocks the maturation of <I>Borrelia
burgdorferi</I> in the mid-gut of infected deer ticks. Published work in non-human primates showed that TNX-4800 was 95% effective in
preventing infection after 6 days of exposure to ticks infected with Borrelia burgdorferi.<SUP>1 </SUP>TNX-4800 was derived from mAb
2217 by amino acid substitutions in its crystallizable fragment (Fc) domain which served to prolong the serum half-life. <FONT STYLE="font-family: Times New Roman, Times, Serif">A
single administration in the Spring is designed to provide immunity within two days and maintain protective antibody titers for the entire
tick season, providing pre-exposure prophylaxis against Lyme disease without relying on the recipient&rsquo;s immune system to generate
antibodies. By delivering a well-characterized antibody directly, TNX-4800 has been shown to block transmission of the major <I>Borrelia</I>
genospecies from ticks to animals. TNX-4800 also sidesteps the multidose schedules required for OspA vaccines in development<SUP>6</SUP>
and FDA-approved vaccines that have been withdrawn from the market due to concerns about increased risk of autoimmunity.<SUP>7 </SUP>Tonix
intends to advance TNX-4800 through additional clinical trials with the goal of submitting a Biologics Licensing Application (BLA) to
the FDA. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About TNX-4800 Pharmacokinetics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">TNX-4800 was studied in a randomized, double-blind,
sequential dose-escalation study (NCT04863287) that evaluated safety, tolerability, pharmacokinetics (PK), and immunogenicity of TNX-4800
in healthy adults. Forty-four subjects were randomized and 41 completed the study. Subjects received a single subcutaneous (SC) administration
of placebo or TNX-4800 at 0.5, 1.5, 5, or 10 mg/kg. Safety was assessed via clinical and lab evaluations. Drug exposure increased by
approximately 25-times for a 20-times increase in dose. Serum TNX-4800 was measurable at the earliest sampling time of 24 hours, indicating
rapid systemic absorption. TNX-4800 concentrations remained quantifiable for &gt;200 days in 80% of volunteers at the lowest dose and
for up to 350 days in the majority of volunteers at higher doses (i.e., &#8805; 1.5 mg/kg). Mean half-life ranged from 62&ndash;69 days
across groups. Serum concentrations remained quantifiable for up to 12 months in most subjects. Mean exposure for the 10 mg/kg cohort
was less than 20% of the highest exposures in a rat toxicology study. Anti-drug antibodies (ADA) were detected in &lt;10% of treated
subjects, with no impact on PK. Most adverse events were mild or moderate. TNX-4800 was determined to be generally safe and well tolerated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About Lyme Disease&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the United States, Lyme disease is caused by the
bacterium&nbsp;<I>Borrelia burgdorferi</I>. Lyme disease remains the most common vector-borne infection in the United States and its
incidence is climbing each year.<SUP>8</SUP> It occurs most commonly in the Northeast, mid-Atlantic, and upper-Midwest regions. Lyme
disease bacteria are transmitted through the bite of infected <I>Ixodes</I> ticks. Typical&nbsp;symptoms&nbsp;include fever, headache,
fatigue, and a characteristic skin rash called&nbsp;erythema migrans. If left untreated, infection can spread to joints, the heart, and
the nervous system. Laboratory testing is helpful if used correctly and performed with FDA-cleared tests. Although many cases of Lyme
disease can be treated&nbsp;successfully with antibiotics, diagnosis and treatment are often delayed or missed, and even with treatment,
up to 20% of cases may progress to a Post-Treatment Lyme Disease Syndrome (PTLDS) called &ldquo;Chronic Lyme&rdquo; or &ldquo;Long Lyme&rdquo;.
Chronic Lyme is considered an Infection Associated Chronic Illness (IACI), and is a chronic, debilitating disease state characterized
by joint and muscle pain, fatigue and other symptoms.<SUP>9</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><IMG SRC="ex99_001.gif" ALT="">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About <I>Borrelia Burgdorferi</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In infected deer ticks, <I>Borrelia&rsquo;s</I> OspA
lipoprotein binds to tick-gut receptor TROSPA and helps it adhere to the midgut lining. During a tick bite blood meal, <I>Borrelia</I>
downregulates OspA, upregulates OspC, and activates motility genes. <I>Borrelia</I> undergoes a metamorphic-like transformation, becoming
highly flagellated and mobile, which facilitates migration to the tick salivary glands and invasion of human host tissues. During a tick
bite of an animal pre-treated with TNX-4800, the tick ingests host blood containing TNX-4800, which kills and blocks the metamorphic-like
transformation of <I>Borrelia </I>in the tick&rsquo;s midgut preventing transmission of the bacteria. Lyme-causing <I>Borrelia</I>-exposed
or -infected individuals, rarely make antibodies against OspA which allows for people to be reinfected despite having immunity to OspC.
Consequently, we expect that protection against <I>Borrelia</I> would require annual prophylaxis with TNX-4800.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About Monoclonal Antibody Prophylaxis</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Two long-acting monoclonal antibody products<SUP>10,11</SUP>
have won FDA approval for prophylaxis against respiratory syncytial virus (RSV). AstraZeneca (in partnership with Sanofi) markets Beyfortus&trade;
(nirsevimab) and Merck markets Enflonsia&trade; (clesrovimab).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Tonix Pharmaceuticals Holding Corp.*</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Tonix Pharmaceuticals is a fully-integrated biotechnology
company with marketed products and a pipeline of development candidates. Tonix markets FDA-approved TONMYA<SUP>TM</SUP>, a first-in-class,
non-opioid analgesic medicine for the treatment of fibromyalgia, a chronic pain condition that affects millions of adults. TONMYA is
the first new prescription medicine approved by the FDA for fibromyalgia in more than 15 years. TONMYA was investigated as TNX-102 SL.
Tonix also markets two treatments for acute migraine in adults: Zembrace&reg;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;</FONT>SymTouch&reg;
(sumatriptan injection) and Tosymra&reg; (sumatriptan nasal spray). Tonix&rsquo;s development portfolio* is focused on central nervous
system (CNS) disorders, immunology, immuno-oncology, rare disease and infectious disease. TNX-102 SL is being developed to treat acute
stress reaction and acute stress disorder under an Investigator-Initiated IND at the University of North Carolina in the OASIS study
funded by the U.S. Department of Defense (DoD). TNX-102 SL is also in development for major depressive disorder. Tonix&rsquo;s immunology
development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which
is a Phase 2- ready Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention
of allograft rejection and for the treatment of autoimmune diseases. Tonix&rsquo;s rare disease portfolio includes TNX-2900, intranasal
oxytocin potentiated with magnesium, in development for Prader-Willi syndrome and expected to start a potential pivotal Phase 2 study
in 2026. Tonix&rsquo;s infectious disease portfolio includes TNX-801, a vaccine in development for mpox and smallpox, as well as TNX-4800,
a Phase 2- ready long-acting humanized monoclonal antibody for the seasonal prevention of Lyme disease. Finally, TNX-4200 for which Tonix
has a contract with the U.S. DoD&rsquo;s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years, is a small molecule
broad-spectrum antiviral agent targeting CD45 for the prevention or treatment of high lethality infections to improve the medical readiness
of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility
in Frederick, Md</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">* Tonix&rsquo;s product development candidates are investigational new
drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">This press release and further information about Tonix can be found at&nbsp;www.tonixpharma.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><IMG SRC="ex99_001.gif" ALT="">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Citations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><SUP>1</SUP>Schiller ZA, et al. <I>J Clin Invest.</I> 2021 131(11):e144843.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><SUP>2</SUP>Wang Y, et al.. <I>J Infect Dis</I>. 2016. 214(2):205-11.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><SUP>3</SUP>Cavaleri M, et al.. <I>Biologicals</I>. 2024. 85:101745.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><SUP>4</SUP>Abo YN, et al.. <I>Lancet Infect Dis</I>. 2023. 23(12):e533-e546.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><SUP>5</SUP>Ramanathan R, et al.. <I>Vaccine</I>. 2019 Jul 18;37(31):4256-4261.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><SUP>6</SUP>Comstedt P, et al. <I>Vaccine</I>. 2015 33(44):5982-8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><SUP>7</SUP>Connaught&rsquo;s (ImuLyme&trade;) and SmithKline Beecham&rsquo;s
(LYMErix&trade;) Lyme disease vaccines were withdrawn over concerns about an increased risk of autoimmune arthritis triggered by molecular
mimicry, particularly in HLADRB1*0401 (&quot;DR4+&quot;) individuals. Nigrovic LE, et al. <I>Epidemiol Infect.</I> 2007 135(1):1-8. doi:
10.1017/S0950268806007096. Epub 2006 Aug 8. PMID: 16893489; PMCID: PMC2870557.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><SUP>8</SUP>Gomes-Solecki M, et. al. <I>Clin Infect Dis.</I> 2020 70(8):1768-1773.
doi: 10.1093/cid/ciz872. PMID: 31620776; PMCID: PMC7155782.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><SUP>9</SUP>National Academies of Sciences, Engineering, and Medicine.
2025. <I>Charting a Path Toward New Treatments for Lyme Infection-Associated Chronic Illnesses</I>. Washington, DC: The National Academies
Press. https://doi.org/10.17226/28578.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><SUP>10</SUP>May 29, 2025. Sanofi Press Release. &ldquo;Beyfortus public
health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs.&rdquo; https://bit.ly/40DeJGf</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><SUP>11</SUP>June 9, 2025. Merck Press Release. &ldquo;U.S. FDA Approves
Merck&rsquo;s ENFLONSIA&trade; (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease
in Infants Born During or Entering Their First RSV Season&rdquo; https://bit.ly/4kkXDE8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><IMG SRC="ex99_001.gif" ALT="">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking
words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;forecast,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo;
and &ldquo;intend,&rdquo; among others. These forward-looking statements are based on Tonix's current expectations and actual results
could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize
TONMYA and any of our approved products; risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA
regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing;
uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and
development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there
are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation
to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K
for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on March 18, 2025,
and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified
by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Investor Contact</B>s</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Jessica Morris<BR>
Tonix Pharmaceuticals&nbsp;<BR>
investor.relations@tonixpharma.com&nbsp;<BR>
(862) 799-8599&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Brian Korb&nbsp;<BR>
astr partners&nbsp;<BR>
(917) 653-5122&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">brian.korb@astrpartners.com&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Media Contacts<BR>
</B>Mary Ann Ondish</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><IMG SRC="ex99_001.gif" ALT="">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Tonix Pharmaceuticals<BR>
maryann.ondish@tonixpharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Ray Jordan&nbsp;<BR>
Putnam Insights&nbsp;<BR>
ray@putnaminsights.com&nbsp;<BR>
&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>INDICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">TONMYA is indicated for the treatment of fibromyalgia
in adults.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>CONTRAINDICATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">TONMYA is contraindicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In patients with hypersensitivity to cyclobenzaprine
or any inactive ingredient in TONMYA. Hypersensitivity reactions may manifest as an anaphylactic reaction, urticaria, facial and/or tongue
swelling, or pruritus. Discontinue TONMYA if a hypersensitivity reaction is suspected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With concomitant use of monoamine oxidase (MAO) inhibitors
or within 14 days after discontinuation of an MAO inhibitor. Hyperpyretic crisis seizures and deaths have occurred in patients who received
cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitors drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the acute recovery phase of myocardial infarction,
and in patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In patients with hyperthyroidism.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>WARNINGS AND PRECAUTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Embryofetal toxicity: Based on animal data, TONMYA
may cause neural tube defects when used two weeks prior to conception and during the first trimester of pregnancy. Advise females of
reproductive potential of the potential risk and to use effective contraception during treatment and for two weeks after the final dose.
Perform a pregnancy test prior to initiation of treatment with TONMYA to exclude use of TONMYA during the first trimester of pregnancy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><IMG SRC="ex99_001.gif" ALT="">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Serotonin syndrome: Concomitant use of TONMYA
with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic
antidepressants, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors increases the risk of serotonin syndrome, a
potentially life-threatening condition. Serotonin syndrome symptoms may include mental status changes, autonomic instability,
neuromuscular abnormalities, and/or gastrointestinal symptoms. Treatment with TONMYA and any concomitant serotonergic agent should
be discontinued immediately if serotonin syndrome symptoms occur and supportive <B>symptomatic treatment should be initiated. </B>If
concomitant treatment with TONMYA and other serotonergic drugs is clinically warranted, careful observation is advised, particularly
during treatment initiation or dosage increases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Tricyclic antidepressant-like adverse reactions:
Cyclobenzaprine is structurally related to TCAs. TCAs have been reported to produce arrhythmias, sinus tachycardia, prolongation of the
conduction time leading to myocardial infarction and stroke. If clinically significant central nervous system (CNS) symptoms develop,
consider discontinuation of TONMYA. Caution should be used when TCAs are given to patients with a history of seizure disorder, because
TCAs may lower the seizure threshold. Patients with a history of seizures should be monitored during TCA use to identify recurrence of
seizures or an increase in the frequency of seizures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Atropine-like effects: Use with caution in patients
with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure, and in patients taking anticholinergic drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">CNS depression and risk of operating a motor vehicle
or hazardous machinery: TONMYA monotherapy may cause CNS depression. Concomitant use of TONMYA with alcohol, barbiturates, or other CNS
depressants may increase the risk of CNS depression. Advise patients not to operate a motor vehicle or dangerous machinery until they
are reasonably certain that TONMYA therapy will not adversely affect their ability to engage in such activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Oral mucosal adverse reactions: In clinical studies
with TONMYA, oral mucosal adverse reactions occurred more frequently in patients treated with TONMYA compared to placebo. Advise patients
to moisten the mouth with sips of water before administration of TONMYA to reduce the risk of oral sensory changes (hypoesthesia). Consider
discontinuation of TONMYA if severe reactions occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ADVERSE REACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The most common adverse reactions (incidence <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8805;</FONT>2%
and at a higher incidence in TONMYA-treated patients compared to placebo-treated patients) were oral hypoesthesia, oral discomfort, abnormal
product taste, somnolence, oral paresthesia, oral pain, fatigue, dry mouth, and aphthous ulcer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><IMG SRC="ex99_001.gif" ALT="">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>DRUG INTERACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">MAO inhibitors: Life-threatening interactions may
occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other serotonergic drugs: Serotonin syndrome has
been reported.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">CNS depressants: CNS depressant effects of alcohol,
barbiturates, and other CNS depressants may be enhanced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Tramadol: Seizure risk may be enhanced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Guanethidine or other similar acting drugs: The antihypertensive
action of these drugs may be blocked.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>USE IN SPECIFIC POPULATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pregnancy: Based on animal data, TONMYA may cause
fetal harm when administered to a pregnant woman. The limited amount of available observational data on oral cyclobenzaprine use in pregnancy
is of insufficient quality to inform a TONMYA-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
Advise pregnant women about the potential risk to the fetus with maternal exposure to TONMYA and to avoid use of TONMYA two weeks prior
to conception and through the first trimester of pregnancy. Report pregnancies to the Tonix Medicines, Inc., adverse-event reporting
line at 1-888-869-7633 (1-888-TNXPMED).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Lactation: A small number of published cases report
the transfer of cyclobenzaprine into human milk in low amounts, but these data cannot be confirmed. There are no data on the effects
of cyclobenzaprine on a breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should
be considered along with the mother&rsquo;s clinical need for TONMYA and any potential adverse effects on the breastfed child from TONMYA
or from the underlying maternal condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pediatric use: The safety and effectiveness of TONMYA
have not been established.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Geriatric patients: Of the total number of TONMYA-treated
patients in the clinical trials in adult patients with fibromyalgia, none were 65 years of age and older. Clinical trials of TONMYA did
not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult
patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Hepatic impairment: The recommended dosage of TONMYA
in patients with mild hepatic impairment (HI) (Child Pugh A) is 2.8 mg once daily at bedtime, lower than the recommended dosage in patients
with normal hepatic function. The use of TONMYA is not recommended in patients with moderate HI (Child Pugh B) or severe HI (Child Pugh
C). Cyclobenzaprine exposure (AUC) was increased in patients with mild HI and moderate HI compared to subjects with normal hepatic function,
which may increase the risk of TONMYA-associated adverse reactions.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><IMG SRC="ex99_001.gif" ALT="">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Please see additional safety information in the
full Prescribing Information.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>To report suspected adverse reactions, contact
Tonix Medicines, Inc. at 1-888-869-7633, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Indication and Usage</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Zembrace<SUP>&reg;</SUP>&nbsp;SymTouch<SUP>&reg;</SUP>&nbsp;(sumatriptan
succinate) injection (Zembrace) and Tosymra<SUP>&reg;</SUP>&nbsp;(sumatriptan) nasal spray are prescription medicines used to treat acute
migraine headaches with or without aura in adults who have been diagnosed with migraine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Zembrace and Tosymra are not used to prevent migraines.
It is not known if Zembrace or Tosymra are safe and effective in children under 18 years of age.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Important Safety Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Zembrace and Tosymra can cause serious side effects,
including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a
heart attack:</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif"><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt; width: 20px"></TD><TD STYLE="font-size: 10pt; width: 20px">&#8226;</TD><TD STYLE="font-size: 10pt">discomfort
in the center of your chest that lasts for more than a few minutes or goes away and comes back</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font-size: 10pt; vertical-align: top"><TD STYLE="font-size: 10pt; width: 20px"></TD><TD STYLE="font-size: 10pt; width: 20px">&#8226;</TD><TD STYLE="font-size: 10pt">severe
tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font-size: 10pt; vertical-align: top"><TD STYLE="font-size: 10pt; width: 20px"></TD><TD STYLE="font-size: 10pt; width: 20px">&#8226;</TD><TD STYLE="font-size: 10pt">pain
or discomfort in your arms, back, neck, jaw or stomach</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font-size: 10pt; vertical-align: top"><TD STYLE="font-size: 10pt; width: 20px"></TD><TD STYLE="font-size: 10pt; width: 20px">&#8226;</TD><TD STYLE="font-size: 10pt">shortness
of breath with or without chest discomfort</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font-size: 10pt; vertical-align: top"><TD STYLE="font-size: 10pt; width: 20px"></TD><TD STYLE="font-size: 10pt; width: 20px">&#8226;</TD><TD STYLE="font-size: 10pt">breaking
out in a cold sweat</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font-size: 10pt; vertical-align: top"><TD STYLE="font-size: 10pt; width: 20px"></TD><TD STYLE="font-size: 10pt; width: 20px">&#8226;</TD><TD STYLE="font-size: 10pt">nausea
or vomiting</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font-size: 10pt; vertical-align: top"><TD STYLE="font-size: 10pt; width: 20px"></TD><TD STYLE="font-size: 10pt; width: 20px">&#8226;</TD><TD STYLE="font-size: 10pt">feeling
lightheaded</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Zembrace and Tosymra are not for people with risk
factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless
a heart exam shows no problem.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Do not use Zembrace or Tosymra if you have:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif"><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt; width: 20px"></TD><TD STYLE="font-size: 10pt; width: 20px">&#8226;</TD><TD STYLE="font-size: 10pt">history
of heart problems</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font-size: 10pt; vertical-align: top"><TD STYLE="font-size: 10pt; width: 20px"></TD><TD STYLE="font-size: 10pt; width: 20px">&#8226;</TD><TD STYLE="font-size: 10pt">narrowing
of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font-size: 10pt; vertical-align: top"><TD STYLE="font-size: 10pt; width: 20px"></TD><TD STYLE="font-size: 10pt; width: 20px">&#8226;</TD><TD STYLE="font-size: 10pt">uncontrolled
high blood pressure</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font-size: 10pt; vertical-align: top"><TD STYLE="font-size: 10pt; width: 20px"></TD><TD STYLE="font-size: 10pt; width: 20px">&#8226;</TD><TD STYLE="font-size: 10pt">hemiplegic
or basilar migraines. If you are not sure if you have these, ask your provider.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font-size: 10pt; vertical-align: top"><TD STYLE="font-size: 10pt; width: 20px"></TD><TD STYLE="font-size: 10pt; width: 20px">&#8226;</TD><TD STYLE="font-size: 10pt">had
a stroke, transient ischemic attacks (TIAs), or problems with blood circulation</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font-size: 10pt; vertical-align: top"><TD STYLE="font-size: 10pt; width: 20px"></TD><TD STYLE="font-size: 10pt; width: 20px">&#8226;</TD><TD STYLE="font-size: 10pt">severe
liver problems</TD></TR></TABLE>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><IMG SRC="ex99_001.gif" ALT="">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P></DIV>
    <!-- Field: /Page -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font-size: 10pt; vertical-align: top"><TD STYLE="font-size: 10pt; width: 20px"></TD><TD STYLE="font-size: 10pt; width: 20px">&#8226;</TD><TD STYLE="font-size: 10pt">taken
any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or
dihydroergotamine. Ask your provider for a list of these medicines if you are not sure.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font-size: 10pt; vertical-align: top"><TD STYLE="font-size: 10pt; width: 20px"></TD><TD STYLE="font-size: 10pt; width: 20px">&#8226;</TD><TD STYLE="font-size: 10pt">are
taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking
a MAO-A inhibitor. Ask your provider for a list of these medicines if you are not sure.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font-size: 10pt; vertical-align: top"><TD STYLE="font-size: 10pt; width: 20px"></TD><TD STYLE="font-size: 10pt; width: 20px">&#8226;</TD><TD STYLE="font-size: 10pt">an
allergy to sumatriptan or any of the components of Zembrace or Tosymra</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Tell your provider about all of your medical conditions
and medicines you take, including vitamins and supplements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Zembrace and Tosymra can cause dizziness, weakness,
or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Zembrace and Tosymra may cause serious side effects
including:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif"><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt; width: 20px"></TD><TD STYLE="font-size: 10pt; width: 20px">&#8226;</TD><TD STYLE="font-size: 10pt">changes
in color or sensation in your fingers and toes</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font-size: 10pt; vertical-align: top"><TD STYLE="font-size: 10pt; width: 20px"></TD><TD STYLE="font-size: 10pt; width: 20px">&#8226;</TD><TD STYLE="font-size: 10pt">sudden
or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font-size: 10pt; vertical-align: top"><TD STYLE="font-size: 10pt; width: 20px"></TD><TD STYLE="font-size: 10pt; width: 20px">&#8226;</TD><TD STYLE="font-size: 10pt">cramping
and pain in your legs or hips; feeling of heaviness or tightness in your leg muscles; burning or aching pain in your feet or toes while
resting; numbness, tingling, or weakness in your legs; cold feeling or color changes in one or both legs or feet</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font-size: 10pt; vertical-align: top"><TD STYLE="font-size: 10pt; width: 20px"></TD><TD STYLE="font-size: 10pt; width: 20px">&#8226;</TD><TD STYLE="font-size: 10pt">increased
blood pressure including a sudden severe increase even if you have no history of high blood pressure</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font-size: 10pt; vertical-align: top"><TD STYLE="font-size: 10pt; width: 20px"></TD><TD STYLE="font-size: 10pt; width: 20px">&#8226;</TD><TD STYLE="font-size: 10pt">medication
overuse headaches from using migraine medicine for 10 or more days each month. If your headaches get worse, call your provider.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font-size: 10pt; vertical-align: top"><TD STYLE="font-size: 10pt; width: 20px"></TD><TD STYLE="font-size: 10pt; width: 20px">&#8226;</TD><TD STYLE="font-size: 10pt">serotonin
syndrome, a rare but serious problem that can happen in people using Zembrace or Tosymra, especially when used with anti-depressant medicines
called SSRIs or SNRIs. Call your provider right away if you have: mental changes such as seeing things that are not there (hallucinations),
agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font-size: 10pt; vertical-align: top"><TD STYLE="font-size: 10pt; width: 20px"></TD><TD STYLE="font-size: 10pt; width: 20px">&#8226;</TD><TD STYLE="font-size: 10pt">hives
(itchy bumps); swelling of your tongue, mouth, or throat</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font-size: 10pt; vertical-align: top"><TD STYLE="font-size: 10pt; width: 20px"></TD><TD STYLE="font-size: 10pt; width: 20px">&#8226;</TD><TD STYLE="font-size: 10pt">seizures
even in people who have never had seizures before</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The most common side effects of Zembrace and Tosymra
include: pain and redness at injection site (Zembrace only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning
feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions
(Tosymra only) and throat irritation (Tosymra only).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><IMG SRC="ex99_001.gif" ALT="">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Tell your provider if you have any side effect that
bothers you or does not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your
provider.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This is the most important information to know about
Zembrace and Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions
for Use. You can also visit https://www.tonixpharma.com or call 1-888-869-7633.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">You are encouraged to report adverse effects of prescription
drugs to the FDA. Visit&nbsp;www.fda.gov/medwatch,
or call 1-800-FDA-1088.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This press release and further information about
Tonix can be found at&nbsp;www.tonixpharma.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>3
<FILENAME>tnxp-20251229_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20251229.xsd#Cover" roleURI="http://TNXP/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://TNXP/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>tnxp-20251229.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +6spw7xRiXhun8uCbn1MSaGNWbP9w5dzielBtm94HTlKDyckc82PCidFz4LmIfEN -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:TNXP="http://TNXP/20251229" elementFormDefault="qualified" targetNamespace="http://TNXP/20251229">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://TNXP/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="tnxp-20251229_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="tnxp-20251229_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>tnxp-20251229_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex99_001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99_001.gif
M1TE&.#EAM !( /<  /______S/__F?__9O__,___ /_,___,S/_,F?_,9O_,
M,__, /^9__^9S/^9F?^99O^9,_^9 /]F__]FS/]FF?]F9O]F,_]F /\S__\S
MS/\SF?\S9O\S,_\S /\ __\ S/\ F?\ 9O\ ,_\  ,S__\S_S,S_F<S_9LS_
M,\S_ ,S,_\S,S,S,F<S,9LS,,\S, ,R9_\R9S,R9F<R99LR9,\R9 ,QF_\QF
MS,QFF<QF9LQF,\QF ,PS_\PSS,PSF<PS9LPS,\PS ,P _\P S,P F<P 9LP
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M,S.9 #-F_S-FS#-FF3-F9C-F,S-F #,S_S,SS#,SF3,S9C,S,S,S #, _S,
MS#, F3, 9C, ,S,   #__P#_S #_F0#_9@#_,P#_  #,_P#,S #,F0#,9@#,
M,P#,  "9_P"9S "9F0"99@"9,P"9  !F_P!FS !FF0!F9@!F,P!F   S_P S
MS  SF0 S9@ S,P S    _P  S   F0  9@  ,P
M
M
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MB 61(D&:6,4C:M&*"MDA$:.812HFI(M0%&,9E:A&@W#QC%=<8QNGF$0YSA$
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-N(*7WE2F&B5(0   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Dec. 29, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 29,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TONIX PHARMACEUTICALS HOLDING CORP.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001430306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1434750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">26
Main Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Chatham<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(862)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">799-8599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TNXP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="tonix-8k_122925.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://TNXP/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>tnxp-20251229.xsd</File>
    <File>tnxp-20251229_lab.xml</File>
    <File>tnxp-20251229_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tonix-8k_122925.htm">tonix-8k_122925.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tonix-8k_122925.htm": {
   "nsprefix": "TNXP",
   "nsuri": "http://TNXP/20251229",
   "dts": {
    "schema": {
     "local": [
      "tnxp-20251229.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "tnxp-20251229_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tnxp-20251229_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tonix-8k_122925.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://TNXP/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-29",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tonix-8k_122925.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-29",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tonix-8k_122925.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://TNXP/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001999371-25-021194-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001999371-25-021194-xbrl.zip
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M\0L0>*@"->KXT)BQ?%[,DP^-RVQN+'I:/&)Q &^W>29G4&$,O@K>&>3X]L*
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MGJELS%G<YY($[\OW9%"^B%%HB2T4O-=$/*EL;N+5@Y(QI6[Z1&_/-D! !,P
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MF*QK6T"<88;L\U'W;-X\6-U^WC07^-01 ]>W:0 L1$B53+Z8*>[&@&0$,Q*
MX'MVZ(X?A%/-E H1G"7F)&>*K_M4S"ANL@5R1V/""^A1K$0-0Y$94NK-&@^H
MZ$NP^L5B8]^UF%C96KY)-#?<T G\Z6I$],M$!^$'RZ#A8:+1U<7GSJP5?I%O
M"\5B+8VJPJA93Q'\=QCPP&+UPYSZG3JT64 )=LRP'R$?OTTW72=@3I"YFGI
M.4-]>YL.V"3(27W*0:^< GGX?YD,.>',,O=)CP4'Y(+:;)],S,D!:1_+#]_R
MQ=:WZ]Z;XO%IH]&!7X@8R60>V;FT^PVGHWY$<WI\]_+)K-,S>E=JWQC(!B -
M_S5LYICP?W!BT>&W ;4$>P*DHQBDE@/$GS8!E$^MMF.RR0<V_98'2U0NY4OY
MW<>#W3T"TAY_*WS32JW@PZ,G@"A^ZXVHS\2WXC=IPA0,(9\] <PQ8M+1H$I+
M"*V#W7?-*1'!U&)OTP.0M7U2R'L!N>(VM+A@=Z3KVM3940]V8'R?#U"D33Z.
MNIE<>!:=[A/'=1B^XY-]%$_F@\S++]PTF8,*@-^@U45H QQ#"?<DZ++!VW1#
M7 Y00C(%L%2U-.'FV_0)-8(\_BNEB0.3AK$8WT\(0KHN)>$PEX#\,V.5XV.M
M%)5T?2XKJP;.Q>>,:/ALP'SPH4S(]V@7]X5T>( .D5YL?^0C9H$S\3*1HF0G
MPDSKUP%8@[=IP6W/8F@!]# )R&HHX8:^'@D:2;;OZ\G+B2Y,7MNEJ"63$XX>
MSAYS$U\,./.)1)RM]!W-]H<D;18[SP;+K1I-C^4!(5US"07PWGYP3 -6GV,?
MP9F_6^P%HK*F3_1F :7XZ-$S3;X$24.'*WJ"<BT2T694A#ZK:R7<AR81J.A5
M C["6@U<Z?,Z^'KRLLTS!Y@;C<5!0,.!<4L$Q9Y2V&G@^O.W3Y[[(GHK8,9&
M/&:.:W/G@3$?I,?BH"O 1J_CTU\DHU:]N:8IE=<V[S '?>NI5.K0BTRD3?TA
M=_9)/EW_][\*N_F#PYR'+1*VO1M:+-.A0^G6X@96]<X$K@?6N>B!!]!/^FX0
MN/8^*>&S.VX&(S3?^3?I1/>^ZP->JON118U; C"(<"UN'A#],H*DWA?F[]$G
M9 3_!QP./)VCCU/4/V-3R"7FD""!=B[EAYQ+-#D@U@%!K<M0BP_AJP'&@ODP
MM7[]^J)]U3HFO:O&5:L78=2O*Z)N9LA>JWG=;5^U6SW2N#@FK<_-=XV+TQ9I
M7IZ?MWN]]N7%@W@47P*/3U2,(!$+7.A[G&UF23%?*=?N&?5!;_[@J F)78)?
M?8E9G5QVS\FA\*@CC1)&-+7\B0S9,IECUPC1W6- _,V8A9/SP/*?NXK/A[O&
MS7%C!.">Z?=K<;\?'S-=KV8^+/KYPQQB6_]EA-\ >* [R'2W=7%%NJW.9??J
MU2;3=RWS)?2C$_HBI$Y  A=Z&)BUDD*)N#XI5+;,;>(.2#!B^"KT><"92+4F
MQH@Z8*X:1H"O"[52^4_E)T8S. >?>:X?D"U3?V<4?!<3 6%C:*E?,W-['Z+_
M^J+2E1:4KB/#H9:*E59KWW%_+_^CU69'G_M/TCY567B;YI-@'W&UH>W(I-,I
M(,R<I'86\JNT,X$<$( 9S.XS/U6L[1 <Z4&E_=5<+KZ(UB[RK*IYII*5+AMR
M@:6; //$U2P[NV:?+[]^S(L1>[;!+!26$Z7DV.GZU>5%^S/IO&MTSQO-UO55
MN]DXZY%WEV?'[8M3\)W=3O8>'FU87[9:$YB*G(-2FPAW0@41'C,P93$)!U('
M@H"= *WQMW^-=0AHWV+PRK* &@967M.@ ?C=HZ89?=<HQ"*_64!GN)9%/0%A
M6_1)QO>'@1_U&C,_X :U(CP@/M0IP&%@/CUTT4B4RH"#QC$#7GD$W2O9,@:H
MT5.+#>8/5XJXE.\8!ID!M;DUW7\(AWBPFL=H=86R-!/*TG8,UP=[*"N<O0#,
M2%.5 )NNN49W/NW^^#'L&_8/UWRNN</B*^:L ?-\=XP"N&3OBLO*=2^NZ?H%
M&U.3WFOR],? ? $^EWYS/I<2?#[A%@.2@'-8S=2+FY-2HWGC?#WZ_GR#6%KF
MV7Q<+(P4,J7=?*'V/QYI'A42/+JBD[:N%!E2QN]CV/AFTGX_/B^<?_T)AJTH
M]:U!(ETO[F8*Y5)YKY)_)/O@A_\<D_MHAL&\-Y(4;$G;$JNR//P/(NQ+B*Q]
M\AX":V%R&7HO),1RFAM!&)QWPC9N)T=>J4RO3^6F:]M<B%])*+1&1 GT]F].
MG7:W]R0);-F>Y4Z9_\MHF;02Y,+-KA*[F1'(R8BN_CJ9]0M,^%[+W3!-GPFA
M?YUQAQ76%&K.2]-W'_-'PN'/M]J59:N] @&TV*ES"M%[+_ 9"]98[9VELE-M
MU=2:\/'2OW+OG-43X[U&]]-9\49PZ_D3VUT[L?GPZ7IS1(,1M1\]G]*J^4@3
M?^EW(/SDCK$FTKVMN".S\OXB:)8W&.GNK9WU I(8XMZEWC-?L.FC9Y]?-?N.
M"RA97[FW/LJ?C$_='KMT+K_3YS.TNG9J"0P@--RK%:MKXXI-Y;\:%TQ^/1\H
MS#UJ$39A1ACP,>;$8-V8V"9;@&<*$?U%R>_+@Y_7)?[]KVJQL'<@H)G%O)'K
M,.)(A[@#B;YAA>C@4M1G%+AL0NRZ*$][6IY0(QO0;+T$?2D<^Y^,'NM,?D*"
M$D7I^)C ONIN<7N-S*06T2YKM,]<"#\[..W[@NOC3]YM.&971[?/-]/%1,5N
M<=QT?:]6RU0KM?7)T$_7YV2FE%\4B>^A +<]13O*C%M9#Z8>&"?0 *R7]MT)
MZ3/+O2-<%8M/P)B1:N8#&7 +98,+$)2 .28SL<PLN!U: 768&PIK2@1$ V(P
ME3U5!^+V86 5).CZ<ZS2% (<GU!G&KT;N!8,COW08'(,#P79$HR14^8P'Q2T
M[4#?4$;8J4:VF%7H;N]OGF+K@H!//@^ (AC0AHX.B,2Z//N=_Z%1_%CVGU9X
MC->*^ZYK,>K(?1\+,I<H2:Y$"TU-;:]</E@C=T3W FSBW8BGEQ92P'-<Y"3E
M8D5S+[FD(%<2M@I[I'G2)<52/@L-MS=DWM9R)E+WGFMQ ]!RAN<@W"#AUFJV
ME(][>X/W=NNF4MT$6Q+%K&6<'N3)O M00O69,81HAJ0*90IHQ7B26-N9<:2<
MSZJ6OYPI%<V4CL]0)G'7CEQB1%OB7PX&ZZRQ4?A1,F^]RO?:1G0F4;5:C]N#
M3(*N&2/6]T$-*I3-3'&KO_TXEJFVOYQI>ZN9UA8B9/Z#K*N6OGYL3HYKPT^[
MFV!=^1[6+6&X 0:66*:\93R.@;KM]N;=5,P6*T_+?/#5<>QG:\-2_+3G!8SW
M?UZN(MS2]=]L)4=!VR?]53M\'E=67AQ';1J:E9N+E3>O4EB^PIW4:J';&!'#
MHD+<5T:/;X=:(H9^J>M>ZUY'NZ4V2,N]5Z*E3W%(TIO:?=?:$MM_/"7+U=>A
MY(5>5I9"R2*S"$;G;L3AR=PRO<2:P4\26[]7U-D *YY/_D=7,-=[;NT.IH5B
M7UJ*-97)KY7P\FJ7T=+3/'7"'R<JDXOC0L8)_M3%>J1KW*Y->Q]4M]?3J%=A
MXZYFH[9,RC"MYF''"\UW7>/'6?/YVP"+B2)L8E"PCA>?._]CW!K&74$,M8YY
MD2Y$X>'ZG4ENU?[*KMQNZ^AII:?%FC-:W%7EYN+>*AV-XP6FN]$[;GQ<%R8W
MJ<<#2$#/J7^+RPHKK'>TV+/)*+?MF!B9,]*?$D.6LJ#C+7@7A@NQJ84Z$Q<$
M& -A/<(>DJ'OW@4C#/ ]K#U104PVX([:[:3*&_G*\G;)V"[)$MG"5&SO0-4X
MHM9<;I3R<*,4<?V42A.*_4QQ!;!5>R_G4#%GF'>,P<W>OQ_YY2C<6D.M12$O
M)I88HEZGLE-3]5DMZT-Z>FK;S4K[>KB)['#%ZL-*Y!Y*##=/Z?;@'NG$POR"
MJ*>DJ/.E:NH(!)E9D-R!(#NN+ V%@LE6,*RNV>*A5B[3/W74!\DIQ[*F./@=
MAZ&1S0Y,"M[X;,P%] /UH(Z!E2=JR&.B6 S&$\4F]4VAJK5F+,^,[4%6 ELH
M;=%9LAF7_2R9T?\U#X6L]TA+AT9>^E#("Y:H5Y 01SX .#]"K&P "(F&]-'+
M!%E[$"9.[]T5Y-Y-;H98]JY)$/D5(/)S6LYMG#Y-M(2NS^AMIL] >&%*GISB
M$U&<E<+B+$P.&.?BG($_57?[F8VN"TG6@G@_(V^:]7^S:L/:2VY]:P?,)GO9
M?.&A77X:I=KF4>JR86BIA:F38W+,A6&Y>%0NNW8GVP8VL<PT=[.%7?T0/ E#
M@/ELA3OI^J5#HC,#)#HS '!=AT](9T3!RQHLE%(D4N\@#D;_T'1]+TNVT(CC
M6G(Q?Z#=J/Q6.-@&Y^& ?S#0%_CNT*<V"3T\WR P^\>MY)!&9,K5?![?FR$$
M/P9X$2Z/:Z O@J>!+E#2(<5K*\C9U&;$!#]$!<NF&N"NO-F*H2?7\'WP>_!2
M5Q>@J1$* 4/*T FB!3! & 0.0M_A8@2X09#(P$51C,-&O,\#4JN!>.X ^A@%
M1MOI=$L("\'YSDX;9W\MGUY#-C"=X<[L]@L,C"4M9XJ<B@+39NC[6"[OJG,W
MJ$[02^%<S7R(;2Q(DIH 5Z@QY\4.$2-J63)RZ0.[&01$9B1D VXQ4XN8DI(0
M& 0<1C1F]>QJ)!37#D?6R1TTXN&@.R;-\08SD8;Q7$PK[D $B0C[WV% #'"P
MG\5IGUOJ.)4<G8+/5 CMP%Q\/2MH.HU-*R%A<=%"0F/XI5?/YTL+:Z<43TI<
MV39QK&L'JV_,4Z<Z)"I]# >EVN"*/0N0GA#T 1;ZU(>11$>$H%)48_2:HO^"
MSO)!3[G22\Y=614$6#L*]!"K_)=LK+8%M_#DF8BU1X_R,FGRVDAP?GYH Z<:
MG^%64(:;4<(]<Q%27< B>!:D):A2-@.!Q"1$IO#7V5X6S ED*6B6C_UP2!JF
MS1V9\4B=W])Z>W+<F*DKR"R,N8O@0- M"!'1G8'J%G,E4, QLUQ/KO"YGEK:
M0X,2>:4LN8IAVF<6APXB)1&E,B_U7<M"JQ7:F <[ VU];-=D%E X-*>0=J'R
M'O+ZD0O&$4P$Y);UC&J+L^;&K5!SM[D-^N;0(,3-+7-H=VYHF:BJE'@N7H$C
M%_TITL6%.=BNHT@ PP#F1/I3ACO6J#%5!G+6"TBC]OB,J:7\6T1UFTXA:1RC
MEL,< [U/!P?2GEG]!HR5'3I%3IQ3)QQ D@WV!U+ C@\?<9\<V3H][X#W'U-N
M23U%) *$"BCB&<RIYLM>DL+@DJ6.1)16R&WQ;1S<&TTM.@$G(]/26>" >-.Q
MRTUM@6T>J$5:M,!C2%"YPZ(Y8&U'@-"J_4J(+/ ?<)%KN_^PE3%&W&>!N4<Q
ML9$[V <S;N'!6(#JP'=M (#M\96+:30+T&[NI)#.TFE >RJ@O2+]%E<S6PQQ
M%F0%)@R6VL<[D4!Z05]"Q94903#5GZ '--'HSR0+:P60B$-KB(DH@)NF;'J+
M$ +>=TWT%]&(2#HWQ, (HEY@*%-H 9,:9.M2> V9K<?P(OW0'YJN#ZZ!(XY*
MIPT:XJZO,5)2ZM0@04IDNM04\2J>8_GG+PZC(I&]0_<+MD$?J:3 '<=T;9!
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M^XT -^"*G:0C\54UT?6GTI#C):+0Q):+I)!G(+WQ^BQPS"I(Y#)D MO 5:4
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M+GAS9%!+ 0(4 Q0    ( +4]G5N89#;N_0H  '^&   5              "
M ?TS  !T;GAP+3(P,C4Q,C(Y7VQA8BYX;6Q02P$"% ,4    " "U/9U;S"+'
MG50'  #$5P  %0              @ $M/P  =&YX<"TR,#(U,3(R.5]P<F4N
M>&UL4$L! A0#%     @ M3V=6S@3:Y*O&0  JW8  !,              ( !
MM$8  '1O;FEX+3AK7S$R,CDR-2YH=&U02P4&      4 !0 _ 0  E&

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>tonix-8k_122925_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tnxp-20251229.xsd" xlink:type="simple"/>
    <context id="AsOf2025-12-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
        </entity>
        <period>
            <startDate>2025-12-29</startDate>
            <endDate>2025-12-29</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="AsOf2025-12-29" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-12-29" id="Fact000004">0001430306</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-12-29" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-12-29" id="Fact000010">2025-12-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-12-29" id="Fact000011">TONIX PHARMACEUTICALS HOLDING CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-12-29" id="Fact000012">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-12-29" id="Fact000013">001-36019</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-12-29" id="Fact000014">26-1434750</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-12-29" id="Fact000015">26 Main Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-12-29" id="Fact000016">Chatham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-12-29" id="Fact000017">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-12-29" id="Fact000018">07928</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-12-29" id="Fact000019">(862)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-12-29" id="Fact000020">799-8599</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-12-29" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-12-29" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-12-29" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-12-29" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-12-29" id="Fact000025">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-12-29" id="Fact000026">TNXP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-12-29" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-12-29" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
